BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:APG-2449 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of APG-2449\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06687070-2351@assetmemo.bio
DTSTAMP:20261121T005454Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:APG-2449: Phase 1 readout est. (NCT06687070)
DESCRIPTION:APG-2449\, phase 1\, Ovarian Cancer.\nStudy: APG-2449 Monothera
 py or in Combination With PLD in Patients With Platinum-resistant Recurren
 t OC or Advanced ST\nEstimated primary completion: May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/apg-2449#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06687070
URL:https://assetmemo.bio/drug/apg-2449#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03917043-2351@assetmemo.bio
DTSTAMP:20261121T005454Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:APG-2449: Phase 1 readout est. (NCT03917043)
DESCRIPTION:APG-2449\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: APG-24
 49 in Patients With Advanced Solid Tumors\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apg-244
 9#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 917043
URL:https://assetmemo.bio/drug/apg-2449#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
